secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2023-05-16T23:59:59+00:00
Accession:  0001104659-23-061113
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics enters $100M ATM sales agreement with BTIG, terminates prior $40M ATM
--------------------------------------------------------------------------------

- ATM sales agreement with BTIG, LLC authorizes up to $100M in common stock sales at the market.
- Prior ATM with H.C. Wainwright & Co. for up to $40M terminated effective May 15, 2023.
- BTIG will receive a 3% commission on gross proceeds; sales may occur on Nasdaq or in private transactions.
- Company is not obligated to sell any shares; placement notices govern specific sales.
- Registration statement on Form S-3 (File No. 333-254778) effective April 1, 2021 covers the offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465923061113/0001104659-23-061113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465923061113/tm2315915d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-061113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer